Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 563-575 , October 2004

Treatment of cancer-related anemia with epoetin alfa: a review

References 

  1. Ludwig H, Barrett-Lee PJ, Gascon P, Schneider M, Van Belle S. European Cancer Anemia Survey (eECAS) defines factors surrounding anemia in thousands cancer patients. Proc. Am. Soc. Clin. Oncol. 2002;21:387a; (Abstract 1546)
  2. Barrett-Lee PJ, Bailey NP, O'Brien ME, Wager E. Large scale UK audit of blood transfusion requirements and anemia in patients receiving cytotoxic chemotherapy. Br. J. Cancer. 2000;82:93–97
  3. Waters JS, O'Brien ME, Ashley S. Management of anemia in patients receiving chemotherapy [letter]. J. Clin. Oncol. 2002;20:601–602
  4. Tas F, Eralp Y, Basaran M, et al.  Anemia in oncology practice: relation to diseases and their therapies. Am. J. Clin. Oncol. 2002;25:371–379
  5. Casadevall N. Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes. Semin. Oncol. 1998;25(Suppl 7):12–18
  6. Prognostic features in the third MRC myelomatosis trial. Medical Research Council's working Party on Leukemia in Adults. Br J Cancer 1980;42:831–40
  7. Coiffier B. Anemia associated with non-platinum chemotherapy (CT) for Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL. Eur. J. Cancer. 1999;35(Suppl 4):S331; (Abstract 1331)
  8. Rizzo JD, Lichtin AE, Woolf SH, et al.  Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J. Clin. Oncol. 2002;20:4083–4107
  9. Gregory CJ, Eaves AC. Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony response. Blood. 1977;49:855–864
  10. Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 1996;88:1576–1582
  11. Sawada K, Krantz SB, Dai C-H, et al.  Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptor. J. Cell Physiol. 1990;142:219–230
  12. Lacombe C, Da Silva JL, Bruneval P, et al.  Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J. Clin. Invest. 1988;81:620–623
  13. Schuster SJ, Badiavas EV, Costa-Giomi P, Weinmann R, Erslev AJ, Caro J. Stimulation of erythropoietin gene transcription during hypoxia and cobalt exposure. Blood. 1989;73:13–16
  14. Tan CC, Eckardt KU, Firth JD, et al.  Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am. J. Physiol. 1992;263:474–481
  15. Lee-Huang S. Cloning and expression of human erythropoietin cDNA in Escherichia coli. Proc. Natl. Acad. Sci. USA. 1984;81:2708–2712
  16. Liu FK, Suggs S, Lin CH, et al.  Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA. 1985;82:7580–7584
  17. Renchy M, Scoble HA, Kim Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. J. Biol. Chem. 1987;262:17156–17163
  18. Davis JM, Arakawa T, Strickland TW, Yphantis DA. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry. 1987;26:2633–2638
  19. Fukuda MN, Sasaki H, Lopez L, et al.  Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood. 1989;73:84–89
  20. D'Andrea AD, Zon LI. Erythropoietin receptor: subunit structure and activation. J. Clin. Invest. 1990;86:681–687
  21. Mayeux P, Billat C, Jacquot R. The erythropoietin receptor of rat erythroid progenitor cell: characterization and affinity cross-linkage. J. Biol. Chem. 1987;262:13985–13990
  22. Watowich SS, Hilton DJ, Lodish HF. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Mol. Cell. Biol. 1994;14:3535–3549
  23. Witthuhn B, Quelle FW, Silvennoinen O, et al.  JAK2 associates with the erythropoietin receptor and its tyrosine phosphorylated and activated following Epo stimulation. Cell. 1993;74:227–236
  24. Jones SS, D'Andrea AD, Haines LL, Wong GG. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood. 1990;76:31–35
  25. Maouche L, Tournamille C, Hattab C, Boffa G, Cartron J-P, Chrétien S. Cloning of the gene encoding the human erythropoietin receptor. Blood. 1991;78:2557–2563
  26. Noguchi CT, Bae KS, Chin K, Wada Y, Schechter AN, Hankins WD. Cloning of the human erythropoietin receptor gene. Blood. 1991;78:2548–2556
  27. Conrad KP, Benyo DF, Westerhausen-Larsen A, Miles TM. Expression of erythropoietin by the human placenta. FASEB J. 1996;10:760–768
  28. Fenjves ES, Ochoa MS, Cabrera O, et al.  Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors. Transplantation. 2003;75:1356–1360
  29. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999;55:808–820
  30. Heeschen C, Aicher A, Lehmann R, et al.  Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102:1340–1346
  31. Anagnostou A, Liu Z, Steiner M, et al.  Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA. 1994;91:3974–3978
  32. Juul S, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Develop. 1998;52:235–249
  33. Juul SE, Yachnis AT, Rojiani AM, Christensen RD. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr. Dev. Pathol. 1999;2:148–158
  34. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development. 1999;126:3597–3605
  35. Ogilvie M, Yu X, Nicolas-Metral V, et al.  Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J. Biol. Chem. 2000;275:39754–39761
  36. Sasaki R. Pleiotropic functions of erythropoietin. Intern. Med. 2003;42:142–149
  37. Williams DM, Zimmers TA, Pierce JH, et al.  The expression and role of human erythropoietin receptor in erythroid and nonerythroid cells. Ann. N. Y. Acad. Sci. 1994;718:232–243
  38. Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego: erythropoietin has multiple actions. Stem Cells. 2002;20:485–492
  39. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990;248:378–381
  40. Spivak JL, Pham T, Isaacs M, Hankins WD. Erythropoietin is both a mitogen and a survival factor. Blood. 1991;77:1228–1233
  41. Okuno Y, Takahashi T, Suzuki A, et al.  Expression of the erythropoietin receptor on a human myeloma cell line. Biochem. Biophys. Res. Commun. 1990;170:1128–1134
  42. Kayser K, Gabius HJ. Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand. Zentralbl. Pathol. 1992;138:266–270
  43. Komatsu N, Yamamoto M, Fujita H, et al.  Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood. 1993;82:456–464
  44. Yasuda Y, Fujita Y, Matsuo T, et al.  Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis. 2003;24:1021–1029
  45. Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R, Vacca A. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology. 2003;42:246–250
  46. Yoshimura A, Longmore G, Lodish HF. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature. 1990;348:647–649
  47. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem. Biophys. Res. Commun. 2003;307:999–1007
  48. Tucci M, Quatraro C, Dammacco F. Recent advances in understanding the pathogenesis of anemia in multiple myeloma. Int. J. Hematol. 2003;78:121–125
  49. Kalmanti M, Kalmanti T. Committed erythroid progentitors and erythropoietin levels in anemic children with lymphomas and tumors. Pediatric. Hem. Onc. 1989;6:85–93
  50. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med. 1990;322:1689–1692
  51. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 1992;79:1987–1994
  52. Taniguchi S, Dai CH, Price JO, Krantz SB. Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. Blood. 1997;90:2244–2252
  53. Welch RS, James RD, Wilkinson PM, FB. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am 1995;1:261–6
  54. Henke M. Correction of anemia-impact on disease course, prognosis and treatment efficacy, particularly for patients undergoing radiotherapy. Onkologie. 2001;24:450–454
  55. Moez B, Raudell T. A modelling study of feed forward activation in human erythrocyte glycolysis. ACR Acad. Sci. III. 2001;324:185–199
  56. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin. Oncol. 1998;25(Suppl 7):43–46
  57. Cella D. The functional assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin. Hematol. 1997;34(Suppl 2):13–19
  58. Vogelzang NJ, Breitbart W, Cella D, et al., for The Fatigue Coalition. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol 1997;34 (Suppl 2):4–12
  59. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al.  Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000;5:353–360
  60. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer. 2002;95:155–163
  61. Simon AM, Zittoun R. Fatigue in cancer patients. Curr. Opin. Oncol. 1999;11:244–249
  62. Sminia P, Acker H, Eikesdal HP, Kaaijk P, Enger P, Slotman B, et al.  Oxygenation and response to irradiation of organotypic multicellular spheroids of human glioma. Anticancer Res. 2003;23:1461–1466
  63. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, et al.  Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin. Cancer Res. 2001;7:3399–3403
  64. Schouwink H, Oppelaar H, Rueve Kamp M, van der Valk M, Hart G, Rijken P, et al.  Oxygen depletion during and after mtHPC-mediated photodynamic therapy in RIF1 and HMESO 1 tumors. Rad. Res. 2003;159:190–198
  65. Denko NC, Fontana lA, Hudson KM, Sutphn PD, Rychaudhuri S, Altmon R. Investigating hypoxia tumor physiology through gene expression pattern. Oncogene. 2003;22:5907–5914
  66. Laderoute KR, Alarcon RM, Brody MD, Calaoagan JM, Chen EY, Knapp AM, et al.  Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin. Cancer Res. 2000;6:2941–2950
  67. Sevelda P, Gnant MF, Lainz KH. Influence of anemia on local relapse free furvival (LRFS) of premenopausal primary breast cancer patients under adjuvant CMF chemotherapy: an analysis of the Austrian Breast Cancer Study Group. Proc. Am. Soc. Clin. Oncol. 2002;21:65a; (Abstract 257)
  68. Dunphy EP, Petersen IA, Cox RS, Bagshaw MA. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 1989;16:1173–1178
  69. Jatzko GR, Lisborg PH, Denk H, Klimpfinger M, Stettner HM. A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Cancer. 1995;76:1302–1312
  70. Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients. Cancer. 1994;74:2819–2827
  71. Obermair A, Cheuk R, Horwood K, Janda M, Bachtiary B, Schwanzellberger B, et al.  Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results. Cancer. 2001;92:903–908
  72. Glaser CM, Millesi W, Kornek GV, Lang S, Schüll B, Watzinger F. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 2001;50:705–715
  73. Fein DA, Lee WR, Hanlon AL, et al.  Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J. Clin. Oncol. 1995;13:2077–2083
  74. Obermair A, Handisurya A, Kaider A, Sevelda P, Kolbl H, Gitsch G. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review. Cancer. 1998;83:726–731
  75. Marinaccio M, Mele E, DeMarino E, Pansini N. Pretreatment hemoglobin as a prognostic factor in epithelial ovarian cancer. Proc. Am. Soc. Clin. Oncol. 2002;21:216a; (Abstract 863)
  76. French Cooperative Group on Chronic Lymphocytic Leukemia. Natural history of stage a chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990;76:45–57
  77. Solignac M, European Hematology Association. Epidemiological data on anemia during malignant affections. Press Med 2003;32:1368–70
  78. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86:1528–1536
  79. Lee WR, Berkey B, Marcial V, et al.  Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int. J. Radiat. Oncol. Biol. Phys. 1998;42:1069–1075
  80. Wagner W, Hermann R, Hartlapp J, Esser E, Christoph B, Muller MK, et al.  Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther. Onkol. 2000;176:73–80
  81. Walker RH. Special reports: transfusion risks. Am. J. Clin. Pathol. 1987;88:374–378
  82. National Comprehensive Cancer Network. Practice guidelines in oncology. Cancer and treatment-related anemia: v.1.2003. National Comprehensive Cancer Network, Inc.; 2003
  83. Osterborg A, Brandberg Y, Molostova G, Iosava K, Abdulkadyrov K, Hedenus M, et al.  Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J. Clin. Onc. 2002;20:2486–2494
  84. Smith RE, Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, et al.  A dose and schedule-finding study of darbepoetin alpha for the treatment of chronic anemia of cancer. Br. J. Cancer. 2003;88:1851–1858
  85. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 1990;322:1693–1699
  86. Platanias LC, Miller CB, Mick R, et al.  Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J. Clin. Oncol. 1991;9:2021–2026
  87. Abels R. Erythropoietin for anaemia in cancer patients. Eur. J. Cancer. 1993;29A(Suppl 2):S2–S8
  88. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer. 1994;73:2535–2542
  89. Ludwig H, Sundal E, Pecherstorfer M, et al.  Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer. 1995;76:2319–2329
  90. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S, for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218–34
  91. Demetri GD, Kris M, Wade J, Degos L, Cella D, for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412–25
  92. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Blood. 2000;96:434a; (Abstract 916-II)
  93. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol. 2001;19:2875–2882
  94. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–74
  95. Turner R, Anglin P, Burkes R, et al.  Canadian Cancer and Anemia Guidelines Development Group. Epoetin alfa in cancer patients: evidence-based guidelines. J. Pain Symptom Manag. 2001;22:954–965
  96. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur. J. Clin. Pharmacol. 2001;57:411–418
  97. Fallowfield L, Gagnon D, Zagari M, et al.  Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of opoetin alfa in patients receiving nonplatinum chemotherapy. Br. J. Cancer. 2002;87:1341–1353
  98. Marti HH, Gassmann M, Wenger RH, et al.  Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int. 1997;51:416–418
  99. Cerami A, Brines ML, Ghezzi P, Cerami CJ. Effects of epoetin alfa on the central nervous system. Semin. Oncol. 2001;28(Suppl 8):66–70
  100. Buemi M, Cavallaro E, Floccari F, et al.  The pleiotropic effects of erythropoietin in the central nervous system. J. Neuropathol. Exp. Neurol. 2003;62:228–236
  101. Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J. Cereb. Blood Flow Metab. 2003;23:320–330
  102. Chong ZZ, Kang JQ, Maiese K. Erythropoietin: cytoprotection in vascular and neuronal cells. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2003;3:141–154
  103. Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br. J. Pharmacol. 2003;138:1107–1118
  104. O'Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin. Breast Cancer. 2002;3(Suppl 3):S116–S120
  105. Senzer N. Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation. Semin. Oncol. 2002;29(Suppl 19):47–52
  106. O'Shaughnessy J, Vukelja S, Savin M, Holmes FA, Jones M, Royall D, et al. Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data. Breast Cancer Res. Treat. 2002;76:S138; (Abstract 550)
  107. Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin. Oncol. 2001;28(Suppl 8):49–53
  108. Blohmer JU, von Minckwitz G, Paepke S, et al.  Sequential adjuvant chemo-radiotherapy with vs. without erythropoeitin for patients with high-risk cervical cancer-second analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Proc. Am. Soc. Clin. Oncol. 2002;21:206a; (Abstract 823)
  109. Tsuda E, Kawanishi G, Ueda M. The role of carbohydrate in recombinant human erythropoietin. Eur. J. Biochem. 1990;188:405–411
  110. Broudy VC, Lin N, Egrie J, et al.  Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide. Proc. Natl. Acad. Sci. USA. 1988;85:6513–6517
  111. Smith RE, JaiyesimL IA, Meza LA, et al.  Novel erythropoiesis stimulating protein (NESP) for the treatment of anemia of chronic disease associated with cancer. Br. J. Cancer. 2001;84(Suppl 1):24–30
  112. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP. Br. J. Cancer. 2001;84(Suppl 1):3–10
  113. Glaspy J. Introduction (Darbepoetin alfa supplement). Br. J. Cancer. 2001;84(Suppl 1):1–2
  114. Scott SD. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clincial studies. Pharmacotherapy. 2002;22(pt 2):150S–165S
  115. Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br. J. Cancer. 2001;84(Suppl 1):11–16
  116. Glaspy JA, Jadeja JS, Justice G, et al.  Darbepoetin alfa given every 1 or 2 weeks alleviates anemia associated with cancer chemotherapy. Br. J. Cancer. 2002;87:268–276
  117. Zamboni WC, Stewart CF. An overview of the pharmacokinetic disposition of darbepoetin alfa. Pharmacotherapy. 2002;22(pt 2):133S–140S
  118. Casadevall N, Nataf J, Viron B, et al.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002;346:469–475
  119. Locatelli F, Del Vecchio L. Pure red cell aplasia secondary to treatment with erythropoietin. Artificial Organs. 2003;27:755–758
  120. Prabhakar S, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin. Nephrol. 1997;47:331–335
  121. Pece R, de la Torre M, Alcázar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N. Engl. J. Med. 1996;335:523–524
  122. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B, for the Epoetin Alfa Study Group. Management of anemia in patients receiving chemotherapy [letter]. J Clin Oncol 2002;20:602–03
  123. Finch C. Erythropoiesis, Erythropoietin, and Iron. Blood. 1982;60:1241–1246
  124. Cleeland C, Demetri G, Glaspy J, et al.  Identifying hemoglobin level for optimal quality of life: results of an incremental analysis. Proc. Am. Soc. Clin. Oncol. 1999;18:574a; (Abstract 2215)
  125. Nortier JWR. Marginal analysis to identify optimal hemoglobin levels to maximize quality of life improvement in anaemic cancer patients receiving epoetin alfa. Ann. Oncol. 2000;11(Suppl 4):145; (Abstract 666O)
  126. Crawford J, Cella D, Cleeland CS, et al.  Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888–895

PII: S0305-7372(04)00080-5

doi: 10.1016/j.ctrv.2004.04.005

Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 563-575 , October 2004

Article Tools

* Image Usage & Resolution